The present study was conducted to clinically evaluate grepafloxacin (GPFX) in the treatment of otorhinolaryngologic infections, and the following results were obtained. 1. The clinical efficacy was 88.3% for otitis media, 80.0% for otitis externa, 83.7% for sinusitis, 84.6% for tonsillitis, 80.0% for other infections, and 85.1% overall. 2. The bacteriological efficacy by clinical isolate was 91.2% for Gram-positive bacteria, 94.4% for Gram-negative bacteria, and 91.3% overall. 3. Adverse drug reactions, mainly consisting gastrointestinal symptoms, were reported in 9 of 150 patients (6.0%). Abnormal clinical laboratory test values, mainly an increase in s-GPT, were found in 6 of 83 patients (7.2%). 4. The usefulness of GPFX was 85.2% for otitis media, 72.7% for otitis externa, 88.4% for sinusitis, 84.6% for tonsillitis, 80.0% for all other infections, and 84.0% overall. Based on the above tindings, GPFX is there fore considered to be useful in the treatment of otorhinolaryngologic infections.
View full abstract